PARD (Poniard Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Jul. 06, 2026)


What is Poniard Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Poniard Pharmaceuticals  (OTCPK:PARD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Poniard Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Poniard Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PARD vs OBMP, NSPX, ATRX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poniard Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Poniard Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Poniard Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2011 is calculated as:

For example, Poniard Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2011 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2011 (Change)*Current CPI (Sep. 2011)
=0/226.8890*226.8890
=0.000

Current CPI (Sep. 2011) = 226.8890.

Poniard Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200112 12.937 176.700 16.612
200203 2.793 178.800 3.544
200206 10.982 179.900 13.850
200209 4.568 181.000 5.726
200212 80.518 180.900 100.988
200303 1.036 184.200 1.276
200306 86.356 183.700 106.659
200309 1.940 185.200 2.377
200312 0.000 184.300 0.000
200403 4.132 187.400 5.003
200406 4.000 189.700 4.784
200409 0.039 189.900 0.047
200412 0.016 190.300 0.019
200503 0.000 193.300 0.000
200506 0.014 194.500 0.016
200509 0.014 198.800 0.016
200512 0.077 196.800 0.089
200603 0.000 199.800 0.000
200606 0.000 202.900 0.000
200609 0.000 202.900 0.000
200612 0.000 201.800 0.000
200703 0.000 205.352 0.000
200706 0.000 208.352 0.000
200709 0.000 208.490 0.000
200712 0.000 210.036 0.000
200803 0.000 213.528 0.000
200806 0.000 218.815 0.000
200809 0.000 218.783 0.000
200812 0.000 210.228 0.000
200903 0.000 212.709 0.000
200906 0.000 215.693 0.000
200909 0.000 215.969 0.000
200912 0.000 215.949 0.000
201003 0.000 217.631 0.000
201006 0.000 217.965 0.000
201009 0.000 218.439 0.000
201012 0.000 219.179 0.000
201103 0.000 223.467 0.000
201106 0.000 225.722 0.000
201109 0.000 226.889 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.